Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

02-08-2017 | Lymphoma | Article

Efficacy of palonosetron to prevent delayed nausea and vomiting in non-Hodgkin’s lymphoma patients undergoing repeated cycles of the CHOP regimen

Journal: Supportive Care in Cancer

Authors: Bungo Saito, Hidetoshi Nakashima, Maasa Abe, So Murai, Yuta Baba, Nana Arai, Yukiko Kawaguchi, Shun Fujiwara, Nobuyuki Kabasawa, Hiroyuki Tsukamoto, Yui Uto, Hirotsugu Ariizumi, Kouji Yanagisawa, Norimichi Hattori, Hiroshi Harada, Tsuyoshi Nakamaki

Publisher: Springer Berlin Heidelberg

Login to get access

Abstract

Purpose

Few studies have investigated the effect of palonosetron on delayed chemotherapy-induced nausea and vomiting in lymphoma patients receiving the CHOP regimen. We conducted a prospective clinical trial to assess the efficacy of palonosetron in patients receiving the CHOP regimen.

Methods

Complete control (CC: emesis-free and mild nausea) during delayed phase (24–120 h) was the primary endpoint. The secondary endpoint was complete response (CR: emesis-free) during acute (0–24 h), delayed, and overall phases (0–120 h), and CC during acute and overall phases. Palonosetron (0.75 mg) was administered before chemotherapy on day 1 of both the first and second CHOP cycles.

Results

The efficacy of palonosetron in preventing emesis was evaluated in 40 patients. Across two cycles, over 85% of patients achieved CR. As the primary endpoint, the proportion of patients achieving CC in the delayed phase increased from 70% (cycle 1) to 85% (cycle 2). CR rate in the delayed phase increased from 85% (cycle 1) to 95% (cycle 2).

Conclusion

These results suggest that the antiemetic effects during the delayed phase were inferior to those in the acute phase during the first cycle. However, even at the same dose of palonosetron, CR and CC rates increased in the second cycle.
Literature
1.
The Italian Group for Antiemetic (1995) Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy of cancer. N Engl J Med 332:1–5CrossRef
2.
Geling O, Erchler HG (2005) Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 20:1289–1294CrossRef
3.
Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: double-dummy, randomized, comparative phase III trial. Lancet Oncol 10:115–124CrossRef
4.
Di Renzo N, Montanini A, Mannina SD, Dondi A, Muci S, Mancuso S, De Paolis MR, Plati C, Stelitano C, Patti C, Olivieri A, Liardo E, Buda G, Cantaffa R, Federico M (2011) Single-dose palonosetrone for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin’s lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of phase II study from the Gruppo Italiano per lo studio dei Linfomi (GISL). Support Care Cancer 19:1505–1510CrossRef
5.
Choi BS, Borsaru GP, Ballinari G, Voisin D, Di Renzo N (2014) Multicenter phase IV study palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy. Leuk. Lymphoma 55:544–550CrossRef
6.
Miyata Y, Yakushijin K, Inui Y, Imamura Y, Goto H, Mizutani Y, Kurata K, Kakiuchi S, Sanada Y, Minami Y, Kawamoto S, Yamamoto K, Ito M, Tominaga R, Gomyo H, Mizuno I, Nomura T, Kitagawa K, Sugimoto T, Murayama T, Matsuoka H, Minami H (2016) A prospective study of the antiemetic effect of palonosetron in malignant lymphoma patients treated with the CHOP regimen. Int J Hematol 104:682–691CrossRef
7.
Rigacci L, Landi C, Garuso JP, Puccini B, Alterini R, Carrai V, Perrone T, Bosi A (2012) Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regime in Hodgkin lymphoma patients. Leuk Res 36:182–185CrossRef
8.
Molassiotis A, Lee PH, Burke TA, Dicato M, Gascon P, Roila F, Aapro M (2016) Anticipatory nausea, risk factors, and its impact on chemotherapy-induced nausea and vomiting: results from the Pan European Emesis Registry study. J Pain Symptom Manag 51:987–993CrossRef
9.
Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S, 99–04 Palonosetron Study Group (2003) Improvement prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Cancer 98:2473–2482CrossRef
10.
Gralla R, Lichinitser M, Van der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single dose of palonosetron with ondansetron. Ann Oncol 14:1570–1577CrossRef